Aktieanalys

Initiator Pharma Q1 2024: Focus on sealing a deal - Redeye

Redeye Publicerad: 10 May 10:01

Redeye provides a research update following the Q1 report published by Initiator Pharma earlier today. The report did not include any significant surprises as the company continues to operate at a very low cash burn, showing promise for the financial runway ahead. Instead, we continue to argue that the full priority for 2024 will be to find a licensing partner for primarily pudafensine. We reiterate our fair value range with a base case valuation of SEK24 as we continue to have a strong outlook on the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1005741/initiator-pharma-q1-2024-focus-on-sealing-a-deal?utm_source=finwire&utm_medium=RSS

Nyheter om Initiator Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!